Terms: = Melanoma AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Prognosis
80 results:
1. Role of Surgery in Metastatic melanoma and Review of melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
2. KIF22 promotes the proliferation and glycolysis of melanoma by activating egfr/STAT3 signaling.
Zhong Z; Zhong H
Clinics (Sao Paulo); 2023; 78():100307. PubMed ID: 37944197
[TBL] [Abstract] [Full Text] [Related]
3. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract] [Full Text] [Related]
4. Expression and prognostic value of AIM1L in esophageal squamous cell carcinoma.
Zhou L; Gan L; Liu Z
Medicine (Baltimore); 2023 Aug; 102(34):e34677. PubMed ID: 37653730
[TBL] [Abstract] [Full Text] [Related]
5. Treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract] [Full Text] [Related]
6. miRNAs as potential game-changers in melanoma: A comprehensive review.
Abd-Allah GM; Ismail A; El-Mahdy HA; Elsakka EGE; El-Husseiny AA; Abdelmaksoud NM; Salman A; Elkhawaga SY; Doghish AS
Pathol Res Pract; 2023 Apr; 244():154424. PubMed ID: 36989843
[TBL] [Abstract] [Full Text] [Related]
7. A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma.
Yang J; Yang Y; Wei Y; Wei X
Front Med; 2023 Apr; 17(2):275-289. PubMed ID: 36645632
[TBL] [Abstract] [Full Text] [Related]
8. SCAMP3 promotes breast cancer progression through the c-MYC-β-Catenin-SQSTM1 growth and stemness axis.
Ali A; Shafarin J; Muhammad JS; Farhat NM; Hamad M; Soofi A; Hamad M
Cell Signal; 2023 Apr; 104():110591. PubMed ID: 36627007
[TBL] [Abstract] [Full Text] [Related]
9. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
[TBL] [Abstract] [Full Text] [Related]
10. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract] [Full Text] [Related]
11. A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.
Yao K; Zhou E; Cheng C
Cancer Med; 2022 Feb; 11(4):1232-1243. PubMed ID: 35044091
[TBL] [Abstract] [Full Text] [Related]
12. The immunoexpression of epidermal growth factor receptor in cutaneous squamous cell carcinoma.
Nichita MM; Giurcăneanu C; Mihai MM; Ghigulescu M; Beiu C; Negoiţă SI; Popa LG
Rom J Morphol Embryol; 2021; 62(1):201-208. PubMed ID: 34609422
[TBL] [Abstract] [Full Text] [Related]
13. Aloysia Citrodora Essential Oil Inhibits melanoma Cell Growth and Migration by Targeting HB-EGF-egfr Signaling.
Salama Y; Jaradat N; Hattori K; Heissig B
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360915
[TBL] [Abstract] [Full Text] [Related]
14. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations.
Conforti F; Pala L; Pagan E; Rocco EG; Bagnardi V; Montagna E; Peruzzotti G; De Pas T; Fumagalli C; Pileggi S; Pesenti C; Marchini S; Corso G; Marchio' C; Sapino A; Graffeo R; Collet L; Aftimos P; Sotiriou C; Piccart M; Gelber RD; Viale G; Colleoni M; Goldhirsch A
Breast; 2021 Oct; 59():94-101. PubMed ID: 34217971
[TBL] [Abstract] [Full Text] [Related]
15. Construction of autophagy prognostic signature and analysis of prospective molecular mechanisms in skin cutaneous melanoma patients.
Liao S; He J; Liu C; Zhang Z; Liao H; Liao Z; Yu C; Guan J; Mo H; Yuan Z; Liang T; Lu Z; Xu G; Wang Z; Chen J; Jiang J; Zhan X
Medicine (Baltimore); 2021 Jun; 100(22):e26219. PubMed ID: 34087900
[TBL] [Abstract] [Full Text] [Related]
16. Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.
Fukushima H; Iwata Y; Saito K; Sugiura K
J Dermatol; 2021 Aug; 48(8):1291-1295. PubMed ID: 34018641
[TBL] [Abstract] [Full Text] [Related]
17. NRF2 Enables egfr Signaling in melanoma Cells.
Kreß JKC; Jessen C; Marquardt A; Hufnagel A; Meierjohann S
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916908
[TBL] [Abstract] [Full Text] [Related]
18. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
[TBL] [Abstract] [Full Text] [Related]
19. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
Moschos SJ; Eroglu Z; Khushalani NI; Kendra KL; Ansstas G; In GK; Wang P; Liu G; Collichio FA; Googe PB; Carson CC; McKinnon K; Wang HH; Nikolaishvilli-Feinberg N; Ivanova A; Arrowood CC; Garrett-Mead N; Conway KC; Edmiston SN; Ollila DW; Serody JS; Thomas NE; Ivy SP; Agrawal L; Dees EC; Abbruzzese JL
Melanoma Res; 2021 Apr; 31(2):162-172. PubMed ID: 33661190
[TBL] [Abstract] [Full Text] [Related]
20. Determination of hypoxia signature to predict prognosis and the tumor immune microenvironment in melanoma.
Shou Y; Yang L; Yang Y; Zhu X; Li F; Xu J
Mol Omics; 2021 Apr; 17(2):307-316. PubMed ID: 33624645
[TBL] [Abstract] [Full Text] [Related]
[Next]
